Biotechnology

BioCardia

BioCardia released FY2026 Q1 earnings on May 15 After-Market (EST), actual revenue USD 0, actual EPS USD -0.21 (forecast EPS USD -0.165)

BioCardia to Release FY2026 Q1 Earnings on May 15 During-Market EST, Forecast EPS USD -0.165

BioCardia released FY2025 Q4 earnings on March 24 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1858 (forecast USD -0.17)

BioCardia released FY2025 Annual Earnings on March 24 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2341 (forecast USD -1.2)

BioCardia to release FY2025 earnings report on March 24 During-Market EST, forecast EPS USD -1.2

BioCardia Inc's cell therapy enters formal clinical consultation with Japan PMDA

BioCardia released FY2025 Q3 earnings on November 12 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2362 (forecast USD -0.23)

BioCardia released FY2025 9 Months Earnings on November 12 After-Market EST, with actual revenue of USD 0 and EPS of USD -1.2262

BioCardia to Release FY2025 Q3 Earnings on November 12 After-Market EST, Forecast EPS USD -0.23

BioCardia released FY2025 Semi-Annual earnings on August 11 After-Market EST, with actual revenue of USD 0 and EPS of USD -0.9818

BioCardia released FY2025 Q2 earnings on August 11 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4049 (forecast USD -0.5)

BioCardia Reports Q2 2025 Earnings and Plans FDA Meeting

BioCardia to Release FY2025 Q2 Earnings on August 11 After-Market (EST), Forecast Revenue USD 0, EPS USD -0.5

BioCardia Inc. Completes $570,000 Private Placement

BioCardia Inc. Obtains New Patent for Helix Biotherapeutic Delivery System

BioCardia Participates in A.G.P. Virtual Medical Showcase

BioCardia Inc. CEO Acquires Company Common Stock

BioCardia Announces Q1 2025 Financials and Plans to Advance Key Trials

BioCardia released FY2025 Q1 earnings on May 14 During-Market EST, actual revenue USD 0 (forecast USD --), actual EPS USD -0.585 (forecast USD -0.39)

BioCardia Inc Expected to Report a 39-Cent Per Share Loss for Q1 2025

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

BCDA

BioCardia (BCDA) has launched a CardiAMP Phase III trial and advanced the CardiALLO Phase 1/2 study, reporting no safety issues. The FDA has flagged two potential clearance paths for the Helix system, preferring simultaneous approval with CardiAMP. The company reported a Q1 2026 net income of negative $2.259 million and has cut R&D costs following the closure of the CardiAMP HF Trial.

TradingView

Key facts: CardiAMP advances in US, Japan; FDA flags two Helix paths

SBIO

LABU

BioCardia (NASDAQ:BCDA) reported Q1 2026 financial results, showing a net loss of $2.3 million and reduced expenses of $2.3 million. The company achieved FDA breakthrough designation for its cardiac cell therapy for ischemic heart failure and is preparing for a formal submission in Japan. Positive echocardiography data supports regulatory discussions, with a target market of 20,000 patients and a reimbursement potential of $400 million. Management remains optimistic about future approvals and market opportunities.

benzinga_article

ALPS Medical Breakthrough

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

BioCardia Q1 2026 Earnings Call: Complete Transcript

Earnings Watch

BioCardia | 8-K: FY2026 Q1 Revenue: USD 0

BioCardia | 10-Q: FY2026 Q1 Revenue: USD 0

IBBQ

BioCardia, Inc. will host a conference call on May 15, 2026, at 4:30 PM EDT to discuss its Q1 2026 financial results and provide a corporate update. The call will include a Q&A session following management's remarks. Participants can register for the call and will receive dial-in information upon registration. The call will also be available via live webcast, with a replay accessible for a limited time afterward. BioCardia specializes in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.

StockTitan

Invesco Nasdaq Biotechnology ETF

BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026 | BCDA Stock News

BioCardia has announced FDA agreement on two marketing clearance pathways for its Helix Transendocardial Delivery Catheter System, with no safety concerns raised. The Helix system aims for targeted delivery of therapies for heart failure, potentially enhancing partnerships in advanced cardiovascular treatments. The CardiAMP Cell Therapy, leveraging patients' bone marrow cells, has FDA Breakthrough designation. Despite a recent Buy rating for BCDA stock, Spark's AI Analyst rates it as Neutral due to weak financial performance and cash burn, though recent regulatory milestones provide near-term catalysts.

BioCardia(BCDA.US)

Key facts: CardiAMP advances in US, Japan; FDA flags two Helix paths

BioCardia Q1 2026 Earnings Call: Complete Transcript

BioCardia | 8-K: FY2026 Q1 Revenue: USD 0

BioCardia | 10-Q: FY2026 Q1 Revenue: USD 0

BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026 | BCDA Stock News

BioCardia Secures FDA Pathways for Helix Catheter System